OWM
NBIX icon

OneAscent Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

OneAscent Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$433K Buy
4,457
+354
+9% +$37.1K 0.18% 132
2020
Q4 		$393K Buy
+4,103
New +$396K 0.18% 130

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

OneAscent Wealth Management's NBIX Position: Q1 2021 in Review

OneAscent Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 8.6% in Q1 2021, buying an estimated $37.1K and bringing the position to 4,457 shares worth $433K. The position accounts for 0.18% of the portfolio, ranked #132.

OneAscent Wealth Management first reported a position in NBIX in Q4 2020 and has held it in 2 quarters since. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • OneAscent Wealth Management held 4,457 shares of Neurocrine Biosciences worth $433K as of Q1 2021.
  • OneAscent Wealth Management bought 354 Neurocrine Biosciences shares in Q1 2021, an estimated $37.1K.
  • Neurocrine Biosciences made up 0.18% of OneAscent Wealth Management's portfolio in Q1 2021, its #132 holding.
  • OneAscent Wealth Management first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 2 quarters since.
  • 419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on OneAscent Wealth Management's 13F filing for Q1 2021, filed 27 Apr 2021.